Can the novel aldosterone inhibiting drug balcinrenone reduce hyperkalaemia and worsening renal function compared to steroidal mineralocorticoid receptor antagonists in heart failure?

Iris E. Beldhuis; Hiddo J.L. Heerspink; Adriaan A. Voors

doi:10.1002/ejhf.3387

Can the novel aldosterone inhibiting drug balcinrenone reduce hyperkalaemia and worsening renal function compared to steroidal mineralocorticoid receptor antagonists in heart failure?

Iris E. Beldhuis, Hiddo J.L. Heerspink, Adriaan A. Voors^*

^*Corresponding author voor dit werk

Onderzoeksoutput › Academic › peer review

Originele taal-2	English
Aantal pagina's	4
Tijdschrift	European Journal of Heart Failure
DOI's	https://doi.org/10.1002/ejhf.3387
Status	Published - 22-jul.-2024

Toegang tot document

10.1002/ejhf.3387

Handle.net

Permanente koppeling

Andere bestanden en links

Link naar publicatie in Scopus

Document onder embargo

Can the novel aldosterone inhibiting drug balcinrenone reduce hyperkalaemia and worsening renal function compared to steroidal mineralocorticoid receptor antagonists in heart failure?
Final publisher's version, 2,36 MB
Licentie: Taverne
Embargo eindigt: 22/01/2025
Kopie aanvragen

Citeer dit

@article{f4130043cf3e4cf9882e107f212d0ff9,

title = "Can the novel aldosterone inhibiting drug balcinrenone reduce hyperkalaemia and worsening renal function compared to steroidal mineralocorticoid receptor antagonists in heart failure?",

author = "Beldhuis, {Iris E.} and Heerspink, {Hiddo J.L.} and Voors, {Adriaan A.}",

year = "2024",

month = jul,

day = "22",

doi = "10.1002/ejhf.3387",

language = "English",

journal = "European Journal of Heart Failure",